



European Association of Urology



Corrigendum

Corrigendum to “What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021” [Eur Urol 82(1):6–11]

Fabio Turco^{a,b,*}, Andrew Armstrong^c, Gerhardt Attard^d, Tomasz M. Beer^e, Himisha Beltran^f, Anders Bjartell^g, Alberto Bossi^h, Alberto Brigantiⁱ, Rob G. Bristow^{j,k}, Muhammad Bulbul^l, Orazio Caffo^m, Kim N. Chiⁿ, Caroline Clarke^o, Noel Clarke^p, Ian D. Davis^q, Johann de Bono^r, Ignacio Duran^s, Ros Eeles^t, Eleni Efstathiou^u, Jason Efstathiou^v, Christopher P. Evans^w, Stefano Fanti^x, Felix Y. Feng^y, Karim Fizazi^z, Mark Frydenberg^{aa,ab}, Dan George^{ac}, Martin Gleave^{ad}, Susan Halabi^{ae}, Daniel Heinrich^{ag}, Celestia Higano^{ah}, Michael S. Hofman^{ai}, Maha Hussain^{aj}, Nicholas James^{ak}, Rob Jones^{al}, Ravindran Kanesvaran^{am}, Raja B. Khauli^{an}, Laurence Klotz^{ao}, Raya Leibowitz^{ap,aq}, Christopher Logothetis^{ar,as,at}, Fernando Maluf^{au,av}, Robin Millman^{aw}, Alicia K. Morgans^f, Michael J. Morris^{ax}, Nicolas Mottet^{ay}, Hind Mrabti^{az}, Declan G. Murphy^{ba,bb}, Vedang Murthy^{bc}, William K. Oh^{bd}, Onyeonunam Ngozi Ekeke^{be}, Piet Ost^{bf,bg}, Joe M. O’Sullivan^{bh,bi}, Anwar R. Padhani^{bj}, Christopher Parker^{bk}, Darren M.C. Poon^{bl}, Colin C. Pritchard^{bm}, Danny M. Rabah^{bn}, Dana Rathkopf^{bo}, Robert E. Reiter^{bp}, Mark Rubin^{bq,br}, Charles J. Ryan^{bs}, Fred Saad^{bt}, Juan Pablo Sade^{bu}, Oliver Sartor^{bv}, Howard I. Scher^{bo,bw}, Neal Shore^{bx}, Iwona Skoneczna^{by,bz}, Eric Small^{ca}, Matthew Smith^{cb}, Howard Soule^{cc}, Daniel Spratt^{cd}, Cora N. Sternberg^{ce,cf}, Hiroyoshi Suzuki^{cg}, Christopher Sweeney^{ch}, Matthew Sydes^{ci}, Mary-Ellen Taplin^{ch}, Derya Tilki^{cj,ck,cl}, Bertrand Tombal^{cm}, Levent Türkeri^{cn}, Hiroji Uemura^{co}, Hirotugu Uemura^{cp}, Inge van Oort^{cq}, Kosj Yamoah^{cr}, Dingwei Ye^{cs,ct}, Almudena Zapatero^{cu}, Silke Gillesen^{cv,cw,cx,cy,cz,†}, Aurelius Omlin^{cy,da,†}

^a Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; ^b Division of Medical Oncology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy; ^c Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA; ^d University College London Cancer Institute, London, UK; ^e Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA; ^f Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; ^g Department of Urology, Skåne University Hospital, Malmö, Sweden; ^h Genito Urinary Oncology, Prostate Brachytherapy Unit, Goussave Roussy, Paris, France; ⁱ Unit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy; ^j Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; ^k Christie NHS Trust and CRUK Manchester Institute and Cancer Centre, Manchester, UK; ^l Division of Urology, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon; ^m Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy; ⁿ BC Cancer, Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada; ^o Research Department of Primary Care & Population Health, Royal Free Campus, University College London, Rowland Hill St, London, UK; ^p The Christie and Salford Royal Hospitals, Manchester, UK; ^q Monash University and Eastern Health, Victoria, Australia; ^r The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Surrey, UK; ^s Department of Medical Oncology, Hospital

DOI of original article: <https://doi.org/10.1016/j.eururo.2022.02.010>

* Corresponding author. Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland. Tel. +39 3927704290.

† These authors contributed equally.

<https://doi.org/10.1016/j.eururo.2022.04.004>

0302-2838/© 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



Universitario Marques de Valdecilla, IDIVAL, Santander, Cantabria, Spain; ¹The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK; ¹¹Houston Methodist Cancer Center, Houston, TX, USA; ¹²Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; ¹³University of California Davis School of Medicine, Sacramento, CA, USA; ¹⁴Policlinico S. Orsola, Università di Bologna, Bologna, Italy; ¹⁵University of California, San Francisco, San Francisco, CA, USA; ¹⁶Institut Gustave Roussy, University of Paris Saclay, Villejuif, France; ¹⁷Department of Surgery, Monash University, Melbourne, Australia; ¹⁸Prostate Cancer Research Program, Department of Anatomy & Developmental Biology, Faculty of Nursing, Medicine & Health Sciences, Monash University, Melbourne, Australia; ¹⁹Departments of Medicine and Surgery, Duke Cancer Institute, Duke University, Durham, NC, USA; ²⁰Urological Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada; ²¹Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA; ²²Department of Oncology and Radiotherapy, Innlandet Hospital Trust, Gjøvik, Norway; ²³University of British Columbia, Vancouver, British Columbia, Canada; ²⁴Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; ²⁵Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA; ²⁶The Institute of Cancer Research, London, UK; ²⁷Institute of Cancer Sciences, University of Glasgow, Glasgow, UK; ²⁸Division of Medical Oncology, National Cancer Centre, Singapore; ²⁹Department of Urology and the Naef K. Basile Cancer Institute (NKBCI), American University of Beirut Medical Center, Beirut, Lebanon; ³⁰Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; ³¹Oncology institute, Shamir Medical Center, Zerifin, Israel; ³²Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; ³³Department of Genitourinary Medical Oncology, MD Anderson Cancer Centre, Houston, TX, USA; ³⁴Department of Clinical Therapeutics, Alexandra Hospital, University of Athens, Athens, Greece; ³⁵David H. Koch Centre, Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Centre, Houston, TX, USA; ³⁶Beneficiência Portuguesa de São Paulo, São Paulo, SP, Brasil; ³⁷Departamento de Oncologia, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil; ³⁸Patient Advocate, UK; ³⁹Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁴⁰University Hospital Nord St Etienne, St Etienne, France; ⁴¹National Institute of Oncology, University Hospital, Rabat, Morocco; ⁴²Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; ⁴³Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia; ⁴⁴Tata Memorial Centre, Mumbai, India; ⁴⁵Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA; ⁴⁶Department of Surgery, University of Port Harcourt Teaching Hospital, Alakahia, Port Harcourt, Nigeria; ⁴⁷Department of Radiation Oncology, Iridium Network, Wilrijk (Antwerp), Belgium; ⁴⁸Department of Human Structure and Repair, Ghent University, Ghent, Belgium; ⁴⁹Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, Northern Ireland; ⁵⁰Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, Northern Ireland, UK; ⁵¹Mount Vernon Cancer Centre and Institute of Cancer Research, London, UK; ⁵²Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK; ⁵³Comprehensive Oncology Centre, Hong Kong Sanatorium & Hospital, The Chinese University of Hong Kong, Hong Kong; ⁵⁴Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA; ⁵⁵The Cancer Research Chair, College of Medicine, King Saud University, Riyadh, Saudi Arabia; ⁵⁶Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁵⁷University of California Los Angeles, Los Angeles, CA, USA; ⁵⁸Bern Center for Precision Medicine, Bern, Switzerland; ⁵⁹Department for Biomedical Research, University of Bern, Bern, Switzerland; ⁶⁰Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA; ⁶¹Centre Hospitalier de Université de Montréal, Montreal, Canada; ⁶²Instituto Alexander Fleming, Buenos Aires, Argentina; ⁶³Tulane Cancer Center, New Orleans, LA, USA; ⁶⁴Department of Medicine, Weill Cornell Medical College, New York, NY, USA; ⁶⁵Carolina Urologic Research Center, Myrtle Beach, SC, USA; ⁶⁶Rafal Masztak Grochowski Hospital in Warsaw, Warsaw, Poland; ⁶⁷Maria Skłodowska Curie National Research Institute of Oncology, Warsaw, Poland; ⁶⁸UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA; ⁶⁹Massachusetts General Hospital Cancer Center, Boston, MA, USA; ⁷⁰Prostate Cancer Foundation, Santa Monica, CA, USA; ⁷¹University Hospitals Seidman Cancer Center, Cleveland, OH, USA; ⁷²Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA; ⁷³Division of Hematology and Oncology, Meyer Cancer Center, New York Presbyterian Hospital, New York, NY, USA; ⁷⁴Toho University Sakura Medical Center, Chiba, Japan; ⁷⁵Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; ⁷⁶MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK; ⁷⁷Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; ⁷⁸Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; ⁷⁹Department of Urology, Koc University Hospital, Istanbul, Turkey; ⁸⁰Cliniques Universitaires Saint Luc, Brussels, Belgium; ⁸¹Department of Urology, M.A. Aydınlar Acibadem University, Altunizade Hospital, Istanbul, Turkey; ⁸²Yokohama City University Medical Center, Yokohama, Japan; ⁸³Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan; ⁸⁴Radboud University Medical Center, Nijmegen, The Netherlands; ⁸⁵Department of Radiation Oncology & Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa, FL, USA; ⁸⁶Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; ⁸⁷Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; ⁸⁸Department of Radiation Oncology, Hospital Universitario de La Princesa, Health Research Institute, Madrid, Spain; ⁸⁹Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; ⁹⁰Università della Svizzera Italiana, Lugano, Switzerland; ⁹¹Cantonal Hospital, St. Gallen, Switzerland; ⁹²University of Bern, Bern, Switzerland; ⁹³Division of Cancer Science, University of Manchester, Manchester, UK; ⁹⁴Department of Medical Oncology and Haematology, Cantonal Hospital, St. Gallen, Switzerland

The authors regret that Axel Heidenreich was added to the author list in error. The author list is now corrected as above, however the affiliations of remaining authors have been retained.

The authors would like to apologise for any inconvenience caused.